Sign In
Buy AUTL
$1.62
-0.130 (-7.43%)
At Close: Jun 03, 2026
LONDON, April 20, 2021 (GLOBE NEWSWIRE) -- Autolus Therapeutics plc (Nasdaq: AUTL), a clinical-stage biopharmaceutical company developing next-generation programmed T cell therapies, today announced
Autolus Therapeutics announces appointment of Martin Murphy as Non-executive Chairman
07:00am, Monday, 19'th Apr 2021
LONDON, April 19, 2021 (GLOBE NEWSWIRE) -- Autolus Therapeutics plc (Nasdaq: AUTL), a clinical-stage biopharmaceutical company developing next-generation programmed T cell therapies, today announced
Immunocore: 'Off-The-Shelf' T Cell Therapy
11:13am, Monday, 12'th Apr 2021
Immunocore: 'Off-The-Shelf' T Cell Therapy
Autolus Therapeutics to Participate in Investor Conferences Through April
04:01pm, Thursday, 01'st Apr 2021
LONDON, April 01, 2021 (GLOBE NEWSWIRE) -- Autolus Therapeutics plc (Nasdaq: AUTL), a clinical-stage biopharmaceutical company developing next-generation programmed T cell therapies, today announced
Autolus Therapeutics Receives PRIME designation for AUTO1 for the treatment of adult ALL
08:45am, Thursday, 01'st Apr 2021
LONDON, April 01, 2021 (GLOBE NEWSWIRE) -- Autolus Therapeutics plc (Nasdaq: AUTL), a clinical-stage biopharmaceutical company developing next-generation programmed T cell therapies, today announced
Autolus Therapeutics' (AUTL) CEO Christian Itin on Q4 2020 Results - Earnings Call Transcript
02:55pm, Thursday, 04'th Mar 2021
Autolus Therapeutics' (AUTL) CEO Christian Itin on Q4 2020 Results - Earnings Call Transcript
Autolus Therapeutics PLC Sponsored ADR (AUTL) Surges 6.5%: Is This an Indication of Further Gains?
05:19am, Tuesday, 02'nd Mar 2021
Autolus Therapeutics PLC Sponsored ADR (AUTL) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue movi
Autolus Announces Closing of Public Offering and Full Exercise of Option to Purchase Additional ADSs
04:01pm, Friday, 12'th Feb 2021
LONDON, Feb. 12, 2021 (GLOBE NEWSWIRE) -- Autolus Therapeutics plc (Nasdaq: AUTL), a clinical-stage biopharmaceutical company developing next-generation programmed T cell therapies, today announced th
Autolus Announces Pricing of Public Offering
08:42pm, Tuesday, 09'th Feb 2021
LONDON, Feb. 09, 2021 (GLOBE NEWSWIRE) -- Autolus Therapeutics plc (Nasdaq: AUTL), a clinical-stage biopharmaceutical company developing next-generation programmed T cell therapies, today announced th
Autolus Announces Proposed Public Offering in the United States
04:19pm, Monday, 08'th Feb 2021
LONDON, Feb. 08, 2021 (GLOBE NEWSWIRE) -- Autolus Therapeutics plc (Nasdaq: AUTL), a clinical-stage biopharmaceutical company developing next-generation programmed T cell therapies, today announced th
Autolus Therapeutics to Report Fourth Quarter and Full Year 2020 Financial Results and Host Conference Call on March 4
07:00am, Thursday, 04'th Feb 2021
LONDON, Feb. 04, 2021 (GLOBE NEWSWIRE) -- Autolus Therapeutics plc (Nasdaq: AUTL), a clinical-stage biopharmaceutical company developing next-generation programmed T cell therapies, today announced t
Autolus Therapeutics PLC Sponsored ADR (AUTL) Upgraded to Buy: What Does It Mean for the Stock?
12:47pm, Wednesday, 27'th Jan 2021
Autolus Therapeutics PLC Sponsored ADR (AUTL) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the n
Autolus Therapeutics provides business outlook for 2021 & 2022
04:07am, Wednesday, 06'th Jan 2021
• Company prioritizes AUTO1, a potentially transformational treatment for Adult Acute Lymphoblastic Leukemia (ALL), with full data from the AUTO1-AL1 study expected in 2022 • Company intends to
Autolus Therapeutics to participate in Investor Conferences through January
07:00am, Monday, 04'th Jan 2021
LONDON, Jan. 04, 2021 (GLOBE NEWSWIRE) -- Autolus Therapeutics plc (Nasdaq: AUTL), a clinical-stage biopharmaceutical company developing next-generation programmed T cell therapies, today announced t
Autolus Therapeutics presents additional data on AUTO3 in DLBCL during the 62nd ASH Annual Meeting
12:01pm, Monday, 07'th Dec 2020
AUTO3 continues to show a differentiated product profile supporting outpatient administration
